DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Clazakizumab
Clazakizumab
Ixekizumab for the Treatment of Active Psoriatic Arthritis in Adult Patients
First Analysis of the Severe Paediatric Asthma Collaborative in Europe Registry
Institutional Review Board Informed Consent Document for Research
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Immunfarmakológia Immunfarmakológia
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
(INN) for Biological and Biotechnological Substances
Profile of Sarilumab and Its Potential in the Treatment of Rheumatoid Arthritis
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Safety and Tolerability.Pdf
A Review on the Effect of COVID-19 in Type 2 Asthma and Its Management
Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm Laura Runkel Associate Director, Autoimmune/ Inflammation, CNS, Ophthalmology
(INN) for Biological and Biotechnological Substances
Long-Term Survival After Kidney Transplantation
The Signal Pathways and Treatment of Cytokine Storm in COVID-19
Statistical Analysis Plan
CSL's Annual R&D Investor Briefing 2020
Top View
A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
Biologics for Rheumatoid Arthritis1
Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Role of Monoclonal Antibody Drugs in the Treatment of COVID-19
Supplementary Appendix
Antibody Modeling
Clazakizumab in Late Antibody-Mediated Rejection
A Systematic Literature Research for the 2019 Update of the EULAR
Enthesitis in Psoriatic Arthritis (Part 3): Clinical Assessment and Management
Efficacy of New Treatments for Dactylitis of Psoriatic Arthritis: Update of Literature Review
Prioritization of Candidate Causal Genes in GWAS Signals of Asthma in UK Biobank
Anti-Interleukin-6 Therapies for Hospitalized Patients with COVID-19: a Protocol for a Prospective Meta-Analysis of Randomized Trials 19 February 2021
Unintended Immunological Consequences of Biologic Therapy
Translating IL-6 Biology Into Effective Treatments
A Systematic Review and Meta-Analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis
Impact Education AMCP Psoriatic Disease Activity.Pdf
Interleukin-6 Inhibition in the Management of Non-Infectious
Kinase Inhibition in Autoimmunity and Inflammation
Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
Taltz, INN-Ixekizumab
Supplementary Appendix
EULAR Recommendations for the Management of Rheumatoid Arthritis
Ixekizumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Considering New Lessons About the Use of IL-6 Inhibitors in Arthritis
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Study Protocol and Statistical Analysis Plan
Cm4620204covid19protocolv30 Nal.Pdf
(INN) for Biological and Biotechnological Substances
Cimzia (Certolizumab Pegol) (Rheumatoid Arthritis)
Cytokine Targeting in Rheumatoid Arthritis T ⁎ Viet L
20.201 Mechanisms of Drug Actions Sarilumab Case Study
Downloaded from Mitochondrial Surface
2016 Medicines in Development for Autoimmune Diseases
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
COVID-19 and Patients with Immune-Mediated Inflammatory
Psoriatic Arthritis
Abteilung Fachberatung Medizin Recherche Und Synopse Der
Biological DMARD Efficacy in Psoriatic Arthritis
Quantify RA Clinical Outcomes Database